These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 38376698)

  • 1. Access to Innovative Medicines: Regulation Change and Factors Associated with Drug Approval Lag in Malaysia.
    Chow WL; Salleh NAM; Kang TS
    Ther Innov Regul Sci; 2024 May; 58(3):528-538. PubMed ID: 38376698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Delay in Vaccine Access in ASEAN Countries.
    Subsittipong N; Choi J; Kim TH; Han E
    Int J Environ Res Public Health; 2022 Mar; 19(7):. PubMed ID: 35409470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Assessment of Drug Lag for Approved Oncology Targeted Therapies Between Saudi Arabia, the United States, and the European Union.
    Alnuhait M; Alshammari A; Alharbi M; AlOtaibi L; Alharbi R; Khobrani A; Alkhudair N; Alshamrani M; Alrajhi AM
    Ther Innov Regul Sci; 2024 Jul; 58(4):678-686. PubMed ID: 38536660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison between European Medicines Agency and US Food and Drug Administration in Granting Accelerated Marketing Authorizations for Covid-19 Medicines and their Utilized Regulations.
    Ghadanian M; Schafheutle E
    Ther Innov Regul Sci; 2024 Jan; 58(1):79-113. PubMed ID: 37861859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug Lag and Associated Factors for Approved Drugs in Korea Compared with the United States.
    Cho I; Han E
    Int J Environ Res Public Health; 2022 Mar; 19(5):. PubMed ID: 35270550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Speeding Access to Vaccines and Medicines in Low- and Middle-Income Countries: A Case for Change and a Framework for Optimized Product Market Authorization.
    Ahonkhai V; Martins SF; Portet A; Lumpkin M; Hartman D
    PLoS One; 2016; 11(11):e0166515. PubMed ID: 27851831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Empirical Analysis of Japan's Drug Development Lag Behind the United States.
    Nakamura H; Wakutsu N; Murayama S; Suzuki T
    J Clin Pharmacol; 2022 Jul; 62(7):847-854. PubMed ID: 34970781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparing patient access to pharmaceuticals in the UK and US.
    Cohen J; Cairns C; Paquette C; Faden L
    Appl Health Econ Health Policy; 2006; 5(3):177-87. PubMed ID: 17132032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The drug lag and associated factors for orphan anticancer drugs in Japan compared to the United States.
    Nakayama H; Matsumaru N; Tsukamoto K
    Invest New Drugs; 2019 Oct; 37(5):1086-1093. PubMed ID: 29855823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Notable Differences in Drug Lag Between Korea and Japan of New Drugs Between 2009 and 2017.
    Lee SW; Park SH; Song I; Noh Y; Park H; Ha D; Shin JY
    Ther Innov Regul Sci; 2020 Mar; 54(2):418-423. PubMed ID: 32072585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Time to Entry for New Cancer Medicines: From European Union-Wide Marketing Authorization to Patient Access in Belgium, Estonia, Scotland, and Sweden.
    Ferrario A
    Value Health; 2018 Jul; 21(7):809-821. PubMed ID: 30005753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Availability of Investigational Medicines Through the US Food and Drug Administration's Expanded Access and Compassionate Use Programs.
    Puthumana J; Miller JE; Kim J; Ross JS
    JAMA Netw Open; 2018 Jun; 1(2):e180283. PubMed ID: 30646072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significant differences on submission lag following regulation reform for registration of novel therapeutic drugs in Taiwan.
    Sun IC
    Invest New Drugs; 2019 Oct; 37(5):1094-1106. PubMed ID: 30612310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Entry Lag of Innovative Drugs in Russia, 2010-2019.
    Chaplenko A; Gildeeva G; Vlassov V
    Int J Environ Res Public Health; 2021 May; 18(10):. PubMed ID: 34064608
    [No Abstract]   [Full Text] [Related]  

  • 15. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
    Salcher-Konrad M; Naci H; Davis C
    Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cancer Therapy Approval Timings, Review Speed, and Publication of Pivotal Registration Trials in the US and Europe, 2010-2019.
    Lythgoe MP; Desai A; Gyawali B; Savage P; Krell J; Warner JL; Khaki AR
    JAMA Netw Open; 2022 Jun; 5(6):e2216183. PubMed ID: 35687337
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The notorious "drug lag" for oncology drugs in Japan.
    Yonemori K; Hirakawa A; Ando M; Hirata T; Yunokawa M; Shimizu C; Katsumata N; Tamura K; Fujiwara Y
    Invest New Drugs; 2011 Aug; 29(4):706-12. PubMed ID: 21286780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erratum: Eyestalk Ablation to Increase Ovarian Maturation in Mud Crabs.
    J Vis Exp; 2023 May; (195):. PubMed ID: 37235796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early Patient Access to Medicines: Health Technology Assessment Bodies Need to Catch Up with New Marketing Authorization Methods.
    Leyens L; Brand A
    Public Health Genomics; 2016; 19(3):187-91. PubMed ID: 27238553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in the Review Period of Drug Application and a Drug Lag from the FDA and the EMA: An Industry Survey in South Korea Between 2011 and 2020.
    Choi H; Lee H; Park B; Kim C; Lee J
    Ther Innov Regul Sci; 2023 May; 57(3):552-560. PubMed ID: 36539577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.